Genomics Facility

基因组学设施的目的是提供常规和最先进的基因组技术， 支持癌症中心的尖端基因组学研究。常规DNA测序提供DNA 新的DNA克隆和重组载体的序列。其他服务侧重于新的或复杂的 基因组技术，不能在一个单一的实验室容易地开发，特别是考虑到快速 这一技术领域的技术进步。基因组学研究所已经发生了很大的变化， 在过去的几年里，为了跟上中心成员不断变化的需求， 新的基因组技术癌症中心最近购买了Illumina（Solexa）基因组 分析仪，并通过NCI小型设备赠款，一个Illumina BeadStation。这项赠款是由 癌症中心试点赠款，促进了高通量PCR平台的发展。该设施 被所有三个研究项目和几乎每一个癌症中心的研究人员广泛使用。尽管许多 较大的机构将测序和基因组学功能分开，该基金已经开发了一个工作 主要通过对设施人员的交叉培训，建立联合收割机模式，以有效地结合各种服务。这 方法提供稳定性和效率。该设施处理DNA测序和各种基因组学 作为单独的服务。Illumina基因组分析仪应用程序已添加到服务中 由Genomics Facility提供在下一个供资期间，该基金将推出多个 使用Illumina基因组分析仪和Illumina启动子监测表观遗传变化的方法 甲基化阵列。为了响应中心成员对microRNA（miRNA）功能的重大兴趣， 在发育和疾病中，将建立一个高通量Illumina miRNA平台， ABI低密度miRNA阵列目前正在使用的设施。未来的计划还包括 开发实验方案，使研究人员能够在少量细胞中观察基因表达， 例如各种类型的干细胞。

The purpose of the Genomics Facility is to provide routine and state of the art genomic technologies to support cutting edge genomics research of the Cancer Center. Routine DNA sequencing provides DNA sequence of new DNA clones and recombinant vectors. Additional services focus on new or complex genomic technologies that can not be readily developed in a single laboratory, especially given the rapid technological advancements in this technical area. The Genomics Facility has changed considerably over the past several years to keep pace with the changing needs of Center members and the rapid growth in new genomic technologies. The Cancer Center has recently purchased an Illumina (Solexa) Genome Analyzer, and, through an NCI small equipment grant, an Illumina BeadStation. This grant was facilitated by a Cancer Center pilot grant that facilitated the development of a high throughput PCR platform. The Facility is widely used by all three research programs and almost every Cancer Center investigator. Although many larger institutions separate the sequencing and genomics functions, the Facility has developed a working model to combine the services effectively, primarily through cross-training of facility personnel. This approach provides stability and efficiency. The Facility treats DNA sequencing and the various genomics activities as separate services. The Illumina Genome Analyzer applications have been added to services provided by the Genomics Facility. During the next funding period, the Facility will introduce multiple approaches to monitoring epigenetic changes with the Illumina Genome Analyzer and Illumina promoter methylation arrays. In response to a significant interest of Center members in microRNA (miRNA) functions in development and disease, a high throughput Illumina miRNA platform will be established to complement the ABI low density miRNA arrays presently being used by the facility. Future plans also include the development of protocols that will allow investigators to look at gene expression in small numbers of cells, such as various types of stem cells.